Boston Scientific Co. (NYSE:BSX) EVP Sells $197,633.00 in Stock

Boston Scientific Co. (NYSE:BSX) EVP David A. Pierce sold 5,140 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $38.45, for a total transaction of $197,633.00. Following the completion of the sale, the executive vice president now directly owns 27,173 shares of the company’s stock, valued at $1,044,801.85. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of Boston Scientific stock traded up $1.05 during mid-day trading on Friday, reaching $42.98. 12,753,700 shares of the stock were exchanged, compared to its average volume of 7,769,971. The company has a market capitalization of $58.52 billion, a P/E ratio of 29.24, a price-to-earnings-growth ratio of 2.45 and a beta of 0.75. The company has a current ratio of 1.39, a quick ratio of 1.12 and a debt-to-equity ratio of 0.82. The company has a 50-day simple moving average of $39.43. Boston Scientific Co. has a fifty-two week low of $31.56 and a fifty-two week high of $43.02.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.01). The company had revenue of $2.49 billion for the quarter, compared to the consensus estimate of $2.54 billion. Boston Scientific had a return on equity of 24.65% and a net margin of 18.08%. The firm’s revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.33 EPS. On average, equities research analysts expect that Boston Scientific Co. will post 1.55 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of BSX. Quad Cities Investment Group LLC raised its position in shares of Boston Scientific by 9.6% in the 4th quarter. Quad Cities Investment Group LLC now owns 3,424 shares of the medical equipment provider’s stock valued at $123,000 after acquiring an additional 300 shares during the period. Scotia Capital Inc. raised its holdings in Boston Scientific by 4.3% during the 4th quarter. Scotia Capital Inc. now owns 7,240 shares of the medical equipment provider’s stock worth $256,000 after buying an additional 300 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its holdings in Boston Scientific by 60.0% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 800 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 300 shares during the period. Kalos Management Inc. raised its holdings in Boston Scientific by 1.0% during the 4th quarter. Kalos Management Inc. now owns 31,123 shares of the medical equipment provider’s stock worth $1,099,000 after buying an additional 315 shares during the period. Finally, Kaizen Advisory LLC raised its holdings in shares of Boston Scientific by 10.1% in the fourth quarter. Kaizen Advisory LLC now owns 3,632 shares of the medical equipment provider’s stock valued at $128,000 after purchasing an additional 333 shares during the last quarter. 90.68% of the stock is currently owned by institutional investors.

A number of analysts recently commented on BSX shares. Needham & Company LLC reiterated a “buy” rating and issued a $43.00 target price on shares of Boston Scientific in a report on Monday, May 13th. Canaccord Genuity cut their price target on shares of Boston Scientific from $45.00 to $43.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. Jefferies Financial Group boosted their price target on shares of Boston Scientific from $44.00 to $48.00 and gave the company a “positive” rating in a report on Thursday. Piper Jaffray Companies boosted their price target on shares of Boston Scientific from $42.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday. Finally, BTIG Research reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Thursday, April 25th. Four analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $43.63.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Further Reading: Is the QQQ ETF safe?

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.